Novavax, Inc. (NVAX) is listed on NasdaqGS in the Healthcare sector Β· Biotechnology industry. The current price is 10.10, down -2.13% from the previous close. Market cap is approximately $1.7B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
Revenue is contracting at -76.30% year-over-year. Distinguishing cyclical weakness from structural market decline is the central question.
Pharma and biotech are typically valued through risk-adjusted NPV/DCF on the pipeline.
Novavax, Inc. trades in the upper 32% of its 52-week range (6.20β11.97). The uptrend is intact, though how much optimism is already reflected in the price is a separate question worth checking.
The day's high-to-low spread reached 5.86%, with a -2.13% move. Wide sessions frequently follow earnings, filings, or sector news, so identifying the catalyst matters.
Novavax, Inc. (NVAX) is listed on NasdaqGS, with recent volume of 1,746,519 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app